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ABSTRACT
Protein kinase C ζ (PKCζ) is believed to be a promising target for the treatment of
some diseases, including inflammatory diseases, obesity and diabetes. Hit identification
of PKCζ inhibitors was conducted by structure-based modification, virtual screening and
biological evaluation. Among all the compounds selected and synthesized, compound
JW-1-60A showed moderate activity against PKCζ at 30 μM and 100 μM. The molecular
modeling studies showed that the binding mode of JW-1-61A was very close to the
binding mode of JP-3-149, a reported PKCζ inhibitor with very potent activity, which
might partially explain the moderate activity of JW-1-61A. Based on the structure of JW1-60A, we will synthesize a series of its analogs and investigate their selectivity against
other kinases in the future.
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CHAPTER 1.

INTRODUCTION

PKC Family
In 1977, protein kinase C (PKC) was first discovered from bovine cerebellum by
Nishizuka’s group. They found this new kinase was able to phosphorylate histone [1].
One of his papers published two years later showed that PKC played an important role in
cell surface signal transduction and tumor promotion. Besides activated by
phosphatidylserine (PS), PKC was also activated by diacylglycerol (DAG) produced
during the inositol phospholipids turnover [2]. Recently, the PKC family has been
reported to consist of at least ten members, which are classified into three classes:
conventional PKCs (α, βI, βII, γ), novel PKCs (δ, ε, μ, θ and η), and atypical PKCs (ζ and
ι/λ) [3].
Most of conventional PKCs are selectively translocated to the plasma membrane
due to their affinity for phosphatidylinositol 4, 5-bisphosphate (PIP2). This phospholipid
plasma membrane generally has the negative charges on the surface, which is favorable
for the recruitment of conventional PKCs. Conventional PKCs contain PKC-α (PRKCA),
PKC-β1, β2 (PRKCB) and PKC-γ (PRKCG). Novel PKCs have the higher affinity for
DAG containing membranes. Novel PKCs include PKC-δ (PRKCD), PKC-ε (PRKCE),
PKC-η (PRKCH) and PKC-θ (PRKCQ). Conventional PKCs and novel PKCs both
possess a C1 domain, which is responsible for binding to the DAG and phorbol 12myristate 13-acetate (PMA), and a C2 domain, which is involved in the calciumdependent phospholipid binding, and a serine/threonine-kinase domain (Figure 1-1).
Atypical PKCs (aPKCs) including ζ (PRKCZ), λ and ι (PRKCI) are a subfamily
of PKC family which require neither Ca2+ nor DAG for activation. Unlike conventional
PKCs and novel PKCs which possess two C1 domains (C1A and C1B domain) and C2
domain, aPKCs have only one atypical C1 domain and PB1 domain instead. The PB1
domain is responsible for the modular protein-protein interactions, resulting in the
regulation of atypical PKCs [4].
PKCζ and Diseases
PKCζ and Inflammatory Diseases
Interestingly, aPKCs, including PKCζ and PKC ι/λ, are involved in distinct
downstream signaling pathways. Lack of PKC ι/λ leads to the lethality of the mouse
embryonic stem cells, while PKCζ deficiency severely impairs the activation of the NFκB pathway, causing the immunological deficiencies of the mice [5-6]. Jorge’s group
found that PKCζ knockout cells showed much less phosphorylation of the RelA in
response to tumor necrosis factor- α (TNF- α). Therefore, they concluded that PKCζ was
able to phosphorylate RelA. They also believed Ser311, whose phosphorylation is
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required for the interaction of RelA and the co-activator CREB-binding protein(CBP),
plays a critical role in phosphorylation of RelA in NF-κB transcriptional activation [7].
So far extensive studies have been reported that PKCζ is involved in the activation of NFκB pathway in various cell types, such as B-cells, T helper cells [6, 8-11]. As a result,
PKCζ has been proposed as a novel target for treating inflammatory disease such as
sepsis [12], psoriasis [13] and asthma [9].
PKCζ and Asthma. Pilar Martin’s group found increased PKCζ level during Th2
differentiation of CD4+ T cells. A lack of PKCζ results in less secretion of Th2 cytokines
both in vitro and in vivo, and an obvious impairment in the nuclear translocation and
tyrosine phosphorylation of Stat6 activation. Most importantly, PKCζ-/- mice show
significant inhibition of ovalbumin-induced allergic airway disease, which reveals that
PKCζ might be a potential target for treatment of asthma [9].
PKCζ and Human Osteoarthritic Chondrocytes. PKCζ was also reported to
engage the regulation of interleukin (IL) -1beta -induced NF-κB signaling in human
osteoarthritic (OA) chondrocytes, subsequently regulating the expression of downstream
mediators of cartilage matrix degradation. It has been know that usually PKCζ level is
up-regulated in OA patients [14].
PKCζ and Human Sepsis. Besides asthma and OA chondrocytes, PKCζ plays an
important role in human peripheral blood monocytes and macrophages. In particular,
Inhibition of PKCζ activity imparts both the activation of NF-κB and IL-1β gene
expression stimulated by bacterial Lipopolysaccharide (LPS). PKCζ serves as a
downstream signaling kinase of RhoA and upstream kinase of TAK1 in cytokine gene
expression in human peripheral blood monocytes and macrophages [15].
PKCζ and Diabetes
PKCζ is involved in insulin-mediated glucose uptake. Insulin stimulates glucose
uptake to the plasma membrane by translocation of glucose transporter 4 (GLUT4).
Peter’s group found that impaired glucose tolerance (IGT) is usually associated with
impaired IRS-2-associated PI3 kinase activation and PKCζ expression, which may be
responsible for the insulin resistance in IGT patients [16].
PKCζ and Obesity
Obesity has become a serious health problem in the United States: nearly 30% of
Americans have obesity. Among all the states, West Virginia, Mississippi and Arkansas
have the highest obesity rates at about 35%. If we look at the trend of obesity rates from
1990 to 2014, the obesity rates were keeping increasing. Back to 1990, the average
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obesity rate was about 12%. Right now it has increased more than twofold. Lots of
research efforts have been done in the past few decades, while effective prevention and
treatment of obesity are still lacking. A new finding reported by Dr. Mansbach’s group in
department of medicine of University of Tennessee health science center suggested that
PKCζ plays an important role in fat absorption (Figure 1-2). PKCζ phosphorylates
Sarb1b with the help of ATP, disassembles this 4-protein complex into its components
and releases liver fat binding protein (L-FABP). After that L-FABP is able to bind to
intestinal endoplasmic reticulum (ER) and generate the pre-chylomicron transport
vesicle, which then exerts its functions in fat absorption. Absence of PKCζ or ATP
rendered no increase in ER binding or the production of pre-chylomicron transport
vesicle. So our hypothesis is that, if we can selectively inhibitor PKC zeta, we are able to
stabilize L-FABP and reduce fact absorption [17].
Primarily Hit Identification for PKCζ Inhibitors
Recent Advances in PKCζ Inhibitors and Related Challenges
Some hits from screening libraries or natural compound sources have been
reported as PKCζ inhibitors, while up to now no PKCζ selective inhibitors have been
reported. One major reason limiting the further exploitation of PKCζ as a novel drug
target is the non-selectivity of the reported inhibitors towards the PKC isozymes.
Although aPKCs possess distinctive sequences and structures at the ATP binding pockets
compared with conventional PKCs and novel PKCs, which confers the possibility of
developing specific inhibitors for aPKCs, the two isozymes of aPKCs, PKCι and PKCζ,
share almost identical residues [18]. Therefore, PKCζ selective inhibitors haven’t been
reported so far. Actually recently there were some efforts made aiming to discover the
hits from virtual screening libraries or natural products. A series of 2-(6-phenyl-1Hindazol-3-yl)-1H-benzo[d]imidazoles as selective PKCζ were reported and displayed
good selectivity towards PKC isoforms, however they displayed inhibitory against a
panel of other kinases as well [19]. Among all the compounds, JP-3-149, our previous lab
member synthesized it and gave this name, showed the most potent activity against PKCζ
with IC50 value of 5.6 nM (Figure 1-3). Jing Wu et al. discovered specific PKCζ
inhibitor, PKCzI257.3, and evaluated its activity against EGF-induced breast cancer cell
chemotaxis. Although it indeed displayed selectivity over conventional PKCs and novel
PKCs, no data or studies have been showed that it is able to inhibit the most closely
related isozyme PKCι [20]. Therefore, it is meaningful to discover a novel PKCζ scaffold
with high activity and selectivity over PKC isozymes. In this pilot project thesis, we
mainly used structured-based optimization and virtual screening to identify the hits with
novel scaffolds for PKCζ inhibitors.
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Figure 1-2.

PKCζ is involved in fat absorption

Figure 1-3.

Structures of JP-3-149 and PKCzl257.3
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Hit Identification for PKCζ Inhibitors
PKCζ Hit Identification by Structure Based Optimization. One way we
adopted to identify the hits for PKCζ inhibition was to optimize the structures of reported
compounds. Considering the highly potent activity of JP-3-149, we believe it would be a
very good scaffold for us to modify. So what we did was basically moving this nitrogen
in the imidazole to the 4 or 6 position on phenyl ring of the benzimidazole ring
(Figure 1-4). Here are the structures of the compounds we came up with. The compounds
were made by Dr. Dong-jin Hwang in Dr. Miller’s group. For the DJ-V-181, we kept the
rest part of DJ-V-181 the same as what JP-3-149 has, and tried to see if this new scaffold
would make any changes to the activity. DJ-V-155 has a phenol attached to
benzimidazole ring instead of a N-methyl piperazine ring. DJ-V-185 has a
methoxylphenol instead of just a phenol. Similarly, we designed and synthesized JW-160A which possesses a methyl piperazine ring and a phenyl moiety at the other end. And
from the molecular docking studies, JW-1-60A showed a very interesting binding mode,
which is very similar to what JP-3-149 showed.
PKCζ Hit Identification by Virtual Screening. Recently, extensive reports
showed that virtual screening has become a very popular technique at the initial stage of
drug discovery due to its low cost and high efficiency. Lots of structures have been
identified as novel leads for the drug targets using this technique. In this pilot project, a
receptor-based virtual screening was performed to identify novel PKCζ inhibitors. About
360 K compounds from a library of University of Cincinnati were used to undergo the
virtual screening. The compounds were first filtered according to Lipinski’ Rule and drug
like properties. Crystal structure 3EZR was downloaded from PDB and prepared. The
Virtual Screening workflows includes glide HTVS, glide SP and glide XP. Only 10% of
the compounds with the best docking scores were retained and advance into the next
round. After these docking steps, twenty five compounds were picked and evaluated for
their activity against PKCζ via enzyme based assay.
Among all the compounds selected and synthesized, compound JW-1-60A
showed the most potency with an IC50 value close to 50 μM. Currently our project is still
underway. A series of compounds based on the structure of JW-1-60A may further be
designed, synthesized and investigated for their activity. Their selectivity against the
general panel of kinases, including the most closely related isoenzyme PKCι will also be
investigated. If they show selectivity towards the other kinases, cell assays and structure
modifications will be performed as the next steps.
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Figure 1-4. Structure optimization of JP-3-149 and molecular structures of DJ-VDJ181,
DJ-V-185,
DJ-V-155
and
JW-1-60A.
V-181,
DJ-V-185,
DJ-V-155
and
JW-1-60A.
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CHAPTER 2.

METHODS

ADP-GloTM Kinase Assay
Before testing the activity of the compounds, first we performed the method
optimization for the ADP-GloTM Kinase Assay by optimizing the incubation time,
reaction volume and the ratio of components. The activity of two PKCζ inhibitors,
Go6850 and JP-3-149, was evaluated to see if the assay worked well (Figure 2-1).
Briefly, the activities of the compounds were measured by quantifying the amount
of ADP produced during the reaction. The assay was based on the protocol provided by
Promega with some modifications. 1 x Reaction buffer A supplemented with 50 μM DDT
containing10 μL of kinase (10 ng), 5 μL of CREBtide (1 ng), 5 μL of pure ATP (50 μM,
final concentration) and 5 μL of inhibitor (achieved through third-fold serial dilution) was
used as the reaction buffer. The mixtures were incubated at the room temperature for 3
hours or longer time. After that, 5 μL of ADP-GloTM reagent was added to each well and
the mixtures were incubated at room temperature for 40 minutes or any desired time.
Then, 10 μL of Kinase Detection Reagent was added to each well and the mixtures were
incubated at room temperature for 30 to 60 minutes. The luminescence of the product
was read with BioTek. The average background value was subtracted from the resulting
values.
Virtual Screening
Ligand Preparation
A virtual drug discovery center library from the University of Cincinnati
containing 362,910 compounds was used to undergo the virtual screening via VS
Workflow module (Schrodinger, LLC, New York, NY, 2015). The compounds were first
filtered prior to docking according to Lipinski’ Rule and drug like properties. As a result,
the compounds containing some reactive functional groups, such as acyl halides,
phosphinyl halides and disulfides were removed. After that, all the compounds were
prepared and generated their ionization and tautomeric states with Epik at 7.0 േ 2.0 pH
units. Conformers of the compounds were generated by OPLS_2005 force field, specially
using the ConfGen conformational sampling algorithm.
Receptor Preparation
X-ray structure 3EZR was downloaded from PDB and underwent the protein
preparation. The grid of ATP binding site was defined based on the binding site of the
reported active inhibitor [21]. Both the VdW radius scale factor and the charge scale
factor were specified at 1.0 for the selected residues. After that four hydrogen bond
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Figure 2-1. Dose-response curves of Go6850 and JP-3-149 inhibiting PKCζ
phosphorylation
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constraints were set. Specifically, the oxygen atoms of Glu 331, Val 333, Glu 300 and
Asp 337 were picked in the Workspace. OPLS_2005 force field was used to computer
partial charges.
Molecular Docking
The prepared compounds and generated grid described above were specified in
the Ligand section and Receptor grid section, respectively. OPLS2001 was selected as
force field with post-docking minimizations. Docking with Glide HTVS, Glide SP and
Glide XP were all selected. And in each docking method, flexible docking was chosen
and at least 3 constrains among total 4 constrains were used for the grid during docking
process. Only 10% of the compounds with the best docking scores were allowed to be
kept and advance into the next round. All the good scoring states of each ligand docked
with Glide HTVS and SP were retained, while only the best scoring pose was retained for
compounds docked with Glide XP.
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CHAPTER 3.

RESULTS

Activity of DJ-V-181, DJ-V-155 and DJ-V-185
After the assay worked, we tested the activity of these three compounds. To our
surprise, none of them showed significant activity at 10 or 3 μM against PKC-zeta
(Figure 3-1). The positive control, JP-3-149, showed almost 100% inhibition
Figure 3-2 shows the binding mode of JP-3-149. This nitrogen in the imidazole of
JP-3-149 does form hydrogen bond with Tyr332, so we think it may be very critical for
its binding and this might explain why DJ-V-181, DJ-V-155 and DJ-V-185 didn’t show
activity against PKC-zeta at 10 or 3 μM.
Based on this conclusion and the molecular studies, another four compounds were
designed. Instead of removing the nitrogen away from the indazole ring, we are trying to
add an extra nitrogen to the benzimidazole. Besides, some modifications on the methyl
piperazine ring will also be conducted to improve the hydrogen bindings (Figure 3-3).
Activity of JW-1-60A
As Figure 3-4 shows, at 10 μM JW-1-60A didn’t show any inhibition either,
while at 30 μM and 100 μM, we can see its significant inhibition against PKC-ζ. The
binding mode of JW-1-60A was examined by molecular modeling studies using
Schrodinger Molecular Modeling Suite 2015. Figure 3-5 shows the overall binding
modes of JW-1-60A (orange tube model) and JP-3-149 (purple tube model) in the ATPbinding site pocket of the PKCζ (3EZV). In particular, their piperazine rings approach
deep into the hinge region. At the other end, their phenyl moieties place at almost the
same location. We believe their similar binding modes partially explain the activity of
JW-1-60A. They both extend from the hinge region and reach another pocket formed
basically by two loops, and band in the middle. As reported by the John’s group, JP-3149 would form one hydrogen bond with Asp 331 and two hydrogen bonds with Val 332,
respectively. An additional hydrogen bond between its phenol and Glu 300 of helix C
was also observed as well. However, JW-1-60A shows less interactions compared with
JP-3-149. Only one hydrogen bond with Tyr 332 is formed. Interestingly, the overall
location of JW-1-60A is shallower inside the pocket than the location of JP-3-149, which
we believe might be another factor leading to the worse activity of JW-1-60A than JP-3149.
Activity of 25 Compounds Selected from Virtual Screening
Figure 3-6 shows the structures of the selected compounds. Unfortunately, none
of the compound selected from Virtual Screening showed significant activity against
PKCζ at 10 μM or 3 μM. The positive control used was Go6850 (Figure 3-7).
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Figure 3-1.

Inhibition of PKCζ by DJ-V-181, 155 and 185 at 3 μM and 10 μM

Figure 3-2.

Molecular binding mode of JP-3-149
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Figure 3-3.

The structures of DJ-1, DJ-2, DJ-3, DJ-4

Figure 3-4.

Dose-response curves of JW-1-60A inhibiting PKCζ
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Figure 3-5.

Superposition of JP-3-149 and JW-1-60A
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Figure 3-6.

Molecular structures of compounds selected from virtual screening
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Figure 3-7.
screening

The screen results of the 25 compounds selected from virtual
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CHAPTER 4.

DISCUSSION

Novel PKCζ inhibitor, JW-1-60A, was designed and synthesized. JW-1-60A
showed moderate activity against PKCζ. Molecular modeling studies were performed to
examine the binding of JW-1-60A in PKCζ crystal structure. Based on the binding mode
of JW-1-60A and JP-3-149 (Figure 3-5), we came up with some ideas about future
modifications of JW-1-60A. Like we can change the isopropyl phenyl to phenol to take
advantage of the interactions with Glu 300. Or we can incorporate an indazole ring to the
linker in order to form hydrogen binds with Val 333 and Glu 331, and also make the
structure more rigid.
The binding mode of JW-1-60A was very close to the binding mode of JP-3-149,
which might partially explain the moderate activity of JW-1-60A. In summary, JW-160A represents a novel scaffold of PKCζ inhibitors, which might be used to generate a
series of its analogs with potent activity and high in the future. Furthermore, this
compound will be investigated its selectivity against the other isoforms of PKC family
and other kinases later.
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